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2 episodes of surgical debridement
during the first month. The lesions
began to improve in the second month
of medical therapy, when skin graft-
ing was performed. The patient
remained well and was discharged
after almost 3 months. Medications
were continued for a total period of 6
months. The patient has been well for
>2 years. 
P. insidiosum in tissues resembles
agents of zygomycosis morphologi-
cally but, unlike the latter, rarely stains
with hematoxylin and eosin. Various
immunostainings also help identify
the organism (4). With the exception
of the facial-cranial form of the dis-
ease in the United States (5), most
cases in Thailand occur in patients
with chronic hemolytic anemia; tha-
lassemia-hemoglobinopathy is the
most common underlying disease.
Major clinical manifestations include
ocular and craniofacial infections in
healthy children, arteritis usually orig-
inating from lower extremities, and
chronic subcutaneous abscesses.
Treatment options reported to be
successful include supersaturated
potassium iodide for the chronic cuta-
neous form (2), a combination of
terbinafine and itraconazole in a single
case of an acute, severe ocular, subcu-
taneous infection (6), and therapeutic
vaccination for severe infections
involving major arteries (7,8) in con-
junction with surgery. The first case
suggested that, with chronic pythiosis
involving the aorta, effective manage-
ment is difficult. In the second case,
the laboratory was familiar with P.
insidiosum  isolation procedures;
therefore, a quick diagnosis was made
and early treatment was instituted.
This early form of cutaneous pythiosis
is rarely diagnosed properly by most
clinical and pathologic laboratories.
Human cases probably occur world-
wide (9) but are underrecognized and
thus, misdiagnosed (5). More research
into the pathogenesis, diagnosis, and
new treatment modalities is urgently
needed.
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Rift Valley Fever
Potential, Arabian
Peninsula
To the Editor: Rift Valley fever
(RVF) virus causes severe disease,
abortion, and death in domestic ani-
mals (especially young sheep, cattle,
and goats) in Africa and the Arabian
Peninsula. Humans are infected by
mosquitoes, which maintain epizootic
transmission, or through exposure to
infected animal tissue. Although
human disease may be mild, some-
times severe retinitis, meningoen-
cephalitis, or hemorrhagic fever syn-
dromes may develop in patients. In
Africa, epizootics and associated
human epidemics usually follow
heavy rainfall (1).
RVF was first confirmed outside
Africa in September 2000. The out-
break in southwestern coastal Saudi
Arabia and neighboring coastal areas
of Yemen resulted in an epizootic with
>120 human deaths and major losses
in livestock populations from disease
and slaughter (2,3). RVF virus isolat-
ed from the floodwater mosquito
Aedes vexans arabiensis during the
outbreak was closely related to strains
from Madagascar (1991) and Kenya
(1997), which suggests that the virus
was imported through infected mos-
quitoes or livestock from East Africa
(3). The Arabian outbreak followed
518 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 12, No. 3, March 2006LETTERS
increased rainfall in nearby highlands
that flooded the coastal areas and cre-
ated ideal environments for mosquito
populations similar to those found in
RVF-endemic regions of East Africa
(4). Most RVF activity was associated
with flooded wadi agricultural sys-
tems; no cases were reported in the
mountains or in dry sandy regions,
where surface water does not accumu-
late long enough to sustain mosquito
breeding.
To provide early warning of condi-
tions favorable for RVF epidemics,
the National Aeronautics and Space
Administration (NASA) and the
Department of Defense Global
Emerging Infections Surveillance and
Response System (DoD-GEIS) moni-
tor the satellite-derived normalized
difference vegetation index (NDVI),
which reflects recent rainfall and
other ecologic and climatic factors
(5–7). NDVI anomalies in the high-
lands east of affected areas during the
2000 outbreak (online Appendix
Figure panel A, available from http://
www.cdc.gov/ncidod/EID/vol2no03/
05-0973-G.htm) showed a spatial pat-
tern (although of lower magnitude)
similar to recent anomalies in those
areas (online Appendix Figure panel
B). Greater than normal NDVIs
(20%–60%) were seen in the Sarawat
Mountains, from just northeast of
Djeddah, Saudi Arabia, and south-
westward beyond Jizan and into
Hodeidah governorate in Yemen dur-
ing May and June 2005.
Satellite-derived rainfall estimates
show that widespread rainfall
occurred over most of western Saudi
Arabia and Yemen from mid-April to
mid-June 2005 (8) and accounts for
the high magnitude and spatial pattern
of observed NDVI anomalies in May
and June 2005. Rainfall was concen-
trated in the mountainous regions east
of the Red Sea coast, and was heavi-
est in the areas east of Djeddah and
Jizan, with rainfall totals as high as
120 mm and 60–80 mm, respectively,
during April 2005, compared with the
same period in 2000 (10–50 mm)
(online Appendix Figure panels C and
D) and in southwestern Yemen, with
totals as high as 120 mm during May.
In the area east of Djeddah, total rain-
fall in April 2005 was 150 mm above
the long-term average for that month.
Flooding was reported in Hodeidah
Governorate, Yemen during May (9)
and could be expected in other Red
Sea coastal areas following such
heavy rainfall. This created habitats
appropriate for breeding of mosqui-
toes capable of transmitting RVF, as
occurred in 2000. 
No human cases of RVF have been
reported in Saudi Arabia and Yemen
since the 2000 outbreak, but in
September 2004 the Saudi Ministry of
Agriculture reported that 5 RVF-
seropositive sheep had been identified
during routine surveillance in Jizan
where most infected persons were
exposed during the outbreak in 2000
(2). The primary infection was esti-
mated to have occurred in April 2004
(10). The NDVIs and rainfall patterns
alerted the Yemen and Saudi Arabia
Ministries of Health and Ministries of
Agriculture to conduct field investiga-
tions with the Food and Agriculture
Organization and the World Health
Organization.
Since RVF virus can be maintained
in mosquito eggs for extended periods
and transmitted under favorable con-
ditions (6), the high magnitude of
NDVI and rainfall patterns reported
should prompt heightened veterinary
and human surveillance for RVF in
coastal Arabia and mass vaccination
of susceptible animals. The current
RVF model (7) is indicative of condi-
tions that would promote vector
breeding and could result in an out-
break of mosquitoborne diseases.
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Screening and
Toxigenic
Corynebacteria
Spread
To the Editor: Diphtheria is rare
in countries with high vaccination
coverage, but as seen in Europe in
recent decades, control can disinte-
grate rapidly. When diphtheria is rare,
surveillance is challenging because
clinicians have no experience with the
infection, and disease may be mild or
atypical in vaccinated persons (1).
Clinicians may give inadequate infor-
mation to laboratories, and appropri-
ate investigations may not be per-
formed. Identifying cases is facilitated
if all throat swabs from patients with
pharyngitis are screened by laborato-
ries for corynebacteria, but this proce-
dure is expensive and time consum-
ing. To help balance priorities in diph-
theria surveillance, we evaluated the
potential benefits of microbiologic
screening in preventing secondary
spread of toxigenic corynebacteria in
England and Wales and estimated the
possible consequences of not detect-
ing a case.
The mean number of secondary
cases that might occur per index case
if screening is not undertaken
depends on the mean number of con-
tacts and attack rates, vaccine cover-
age and efficacy, and duration of pro-
tection. Some of these factors are not
known precisely, so we estimated
them within plausible ranges of val-
ues. We varied the number of contacts
per case-patient from 2 to 20.
Secondary attack rates in susceptible
persons are difficult to estimate and
distinguish from carriage rates (2),
and we varied these from 5% to 50%.
Vaccine efficacy in children was var-
ied from 50% to 95%. We estimated
the susceptibility of UK adults at
40% (3), vaccination coverage in
children at 95% (4), and case-fatality
ratio at 6% to 10% (5). For simplici-
ty, the ratio of adults to children
among contacts was assumed to be
1:1. We assumed that without specif-
ic microbiologic identification of
cases, no intervention would take
place and that intervention to protect
contacts is 100% effective. Such
intervention includes early treatment
and isolation of cases, chemoprophy-
laxis, and booster vaccination of con-
tacts. The number of cases that need
to be detected to prevent 1 secondary
case for different numbers of contacts
and attack rates was calculated as the
inverse of the number of secondary
cases that would result from each
case not detected by screening.
The number of cases that must be
detected by microbiologic screening
to prevent 1 secondary case was most
affected by varying the number of
contacts per patient and the secondary
attack rate (Figure). If one assumes
vaccine efficacy of 95%, an attack
rate in susceptible contacts of 5%, and
4 contacts per patient, 1 secondary
case is prevented for every 18 cases
detected; if attack rates are 30%, then
1 secondary case is prevented for <5
index cases detected. If vaccine effi-
cacy was 50%, the number of cases
that would need to be detected to pre-
vent 1 secondary case would fall from
18 to <10 cases for a mean of 4 con-
tacts per case and secondary attack
rates of 5%.
For the 53 toxigenic strains of
corynebacteria detected in England
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Figure. Number of cases needed to detect to prevent 1 secondary case.